A 24‐Week, Phase IIa, Randomized, Double‐Blind, Placebo‐Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis

Objective We undertook this study to explore the efficacy, safety, and tolerability of ziritaxestat, a selective autotaxin inhibitor, in patients with early diffuse cutaneous systemic sclerosis (dcSSc). Methods NOVESA was a 24‐week, multicenter, phase IIa, double‐blind, placebo‐controlled study. Adu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2023-08, Vol.75 (8), p.1434-1444
Hauptverfasser:	Khanna, Dinesh, Denton, Christopher P., Furst, Daniel E., Mayes, Maureen D., Matucci‐Cerinic, Marco, Smith, Vanessa, Vries, Dick, Ford, Paul, Bauer, Yasmina, Randall, Matthew J., Ebrahimpoor, Mitra, Kupcsik, Laszlo, Stiers, Pieter‐Jan, Deberdt, Liesbeth, Prasad, Niyati, Lim, Sharlene, Pujuguet, Philippe, Ahmed, Sohail
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Biomarkers Biopsy Blood Diarrhea Double-Blind Method Double-blind studies Effectiveness Fibrosis Genes Humans Lysophosphatidic acid Placebos Reduction Rheumatology Safety Scleroderma Scleroderma, Diffuse - pathology Skin Skin - pathology Systemic sclerosis Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!